PMV Pharma Q2 net loss $1.2M on $16.2M tax benefit; cash $212.9M; PYNNACLE Phase 2 on track

PMV Pharmaceuticals, Inc.

2024-Q2 EPS reported -$0.32

Net loss narrowed to $1.2M from $17.4M YoY due to $16.2M income tax benefit from NOL sale.
Cash, equivalents, and marketable securities $212.9M; net cash used in operations $17.8M in H1 2024.
Phase 2 monotherapy enrollment on track; >60% sites activated; interim analysis expected by mid-2025.
Phase 1b rezatapopt/pembrolizumab combo adjusted to exclude KRAS SNV; DLTs observed at 1000 mg, then escalated back.
Lease termination at Princeton HQ with $1.42M fee; relocation to smaller space to reduce costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.